Holen Sie sich die Stockscreener-App
97.86
1.45%
1.40
Handel nachbörslich:
97.86
Schlusskurs vom Vortag:
$96.46
Offen:
$96
24-Stunden-Volumen:
733.61K
Relative Volume:
1.04
Marktkapitalisierung:
$6.50B
Einnahmen:
$136.86M
Nettoeinkommen (Verlust:
$-168.69M
KGV:
-34.83
EPS:
-2.81
Netto-Cashflow:
$-113.49M
1W Leistung:
+8.72%
1M Leistung:
+12.87%
6M Leistung:
+70.01%
1J Leistung:
+112.88%
1-Tages-Spanne:
$95.76
$99.04
1-Wochen-Bereich:
$88.00
$99.04
52-Wochen-Spanne:
$43.57
$99.04
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Vergleichen Sie RYTM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
97.86 | 6.41B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-07-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Shulman Joseph of Rhythm Pharma sells $358,891 in shares By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals stock hits all-time high at 95.05 USD By Investing.com - Investing.com Australia
Can Rhythm Pharmaceuticals’ (RYTM) Revenue Growth Offset Persistent Losses in Its Path to Profitability? - simplywall.st
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Rhythm Pharmaceuticals Inc. Forms Bullish Flag — Upside AheadSmart Allocation Stock Pick Insights Gaining Interest - beatles.ru
Rhythm Pharmaceuticals: Unlocking Value as Key Lock-Up Expiry and Setmelanotide Regulatory Milestones Loom - AInvest
Rhythm Pharmaceuticals and the Impending Lock-Up Expiry: A Catalyst for Shareholder Value Realization - AInvest
Rhythm Pharmaceuticals: A Post-Lock-Up Opportunity with Strong Catalysts in Q3 2025 and Beyond - AInvest
Rhythm Pharmaceuticals Lock-Up Agreement Ends on August 9, 2025 - AInvest
Pediatric Obesity Market Expected to Experience Major Growth by 2034, According to DelveInsight | VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski - The Globe and Mail
12 Analysts Weigh In on Rhythm Pharmaceuticals: A Comprehensive Analysis of Ratings and Price Targets - AInvest
Rhythm Pharmaceuticals Exceeds Q2 Expectations, Maintains Buy Rating - AInvest
Leerink Partners Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $102 - 富途牛牛
Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals - TipRanks
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2025 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals stock price target raised to $100 from $80 at H.C. Wainwright - Investing.com Canada
HC Wainwright Raises PT to $100, Maintains Buy Rating on Rhythm Pharmaceuticals. - AInvest
Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term - Yahoo Finance
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Positive Outlook on Rhythm Pharmaceuticals: Strong Growth Potential and Strategic Advancements Support Buy Rating - TipRanks
Guggenheim Raises Rhythm Pharmaceuticals Buy Rating, PT to $120 - AInvest
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates - MSN
Citizens JMP raises Rhythm Pharmaceuticals stock price target to $135 on growth - Investing.com Canada
Rhythm Pharmaceuticals shares rise 3.30% premarket after reporting Q2 2025 earnings. - AInvest
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highligh - GuruFocus
Rhythm Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Rhythm Pharmaceuticals Q2 Revenue Surpasses Estimates, Up 67% YoY - AInvest
Rhythm Pharmaceuticals: Unlocking Value in Rare Disease Innovation and Commercial Scalability - AInvest
Rhythm Pharmaceuticals Achieves 29% QoQ Revenue Growth, Sets Sights on HO Regulatory Filings - AInvest
Rhythm Pharmaceuticals' Q2 2025: Navigating Key Contradictions in Trial Design, Stock Compensation, and Market Dynamics - AInvest
Needham Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $95 - 富途牛牛
Rhythm Pharmaceuticals stock price target raised to $110 from $85 at TD Cowen - Investing.com Canada
Rhythm Pharmaceuticals price target raised to $109 from $100 at Morgan Stanley - TipRanks
Rhythm Pharmaceuticals Q2 2025 Earnings Call Transcript - MarketBeat
Positive Outlook for Rhythm Pharmaceuticals: Strong Revenue Performance and Promising Future Catalysts Justify Buy Rating - TipRanks
Rhythm Pharmaceuticals Q2 2025 slides: Revenue jumps 29%, obesity drugs show promise - Investing.com Canada
Rhythm Pharmaceuticals Fiscal Q2 Net Loss Widens, Revenue Rises - MarketScreener
Rhythm Pharmaceuticals Q2 revenue up 67% yr/yr, net loss widens - MarketScreener
Rhythm Pharmaceuticals Reports Q2 GAAP EPS of -$0.75, Revenue at $48.5 Million - AInvest
Rhythm Pharmaceuticals enrolls first patient in Part C of Phase 1 RM-718 trial - TipRanks
Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q2 Revenue $48.5M, vs. FactSet Est of $43.6M - MarketScreener
Rhythm Pharmaceuticals Q2 2025 Financial Results and Business Update - TradingView
Rhythm Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Update - The Manila Times
Rhythm Pharmaceuticals Q2 net product revenue $48.5mln, raises $189.2mln. - AInvest
Rhythm Pharmaceuticals to Discuss Q2 Financial Results and Corporate Updates on August 5, 2025 - AInvest
How strong is Rhythm Pharmaceuticals Inc. company’s balance sheetDiscover top stock picks for aggressive growth - Jammu Links News
How does Rhythm Pharmaceuticals Inc. generate profit in a changing economyHigh-margin investment plays - Jammu Links News
What are the latest earnings results for Rhythm Pharmaceuticals Inc.Free Investment Timing Strategies - Jammu Links News
Is it the right time to buy Rhythm Pharmaceuticals Inc. stockAchieve breakthrough financial results today - Jammu Links News
Does Rhythm Pharmaceuticals Inc. stock perform well during market downturnsRapid wealth multiplication - Jammu Links News
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):